News

News and Press Releases
Our Research Approach CF Foundation Awards $1 Million to Felix Biotechnology to Develop Novel Phage Therapy

The Foundation’s award will support preclinical studies of a potential phage therapy to treat resistant Pseudomonas infections.

| 2 min read
About the CF Foundation | Our Research Approach CF Foundation Exceeds Initial $100M Infection Research Initiative Funding

This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.

| 7 min read
About the CF Foundation | Clinical Trials | Our Research Approach Cystic Fibrosis Foundation Awards Up to $3.5M to Arrevus Inc. to Develop Treatment for Pulmonary Exacerbations

The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.

| 1 min read
About the CF Foundation | Clinical Trials | Our Research Approach CF Foundation Awards Up to $4.7M to EnBiotix Inc. to Develop Inhaled Antibiotic to Treat Pseudomonas

The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.

| 2 min read
Our Research Approach | Patient Registry | Research CF Foundation Launches Lung Transplant Biorepository and Patient Registry

The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.

| 4 min read
About the CF Foundation | Our Research Approach CF Foundation Launches New Collaboration to Overcome Challenges to Developing Genetic Therapies for CF

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

| 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Nearly $15 Million to Spur Infection Research

Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.

| 4 min read
Our Research Approach CF Foundation Leadership Represents the CF Community Voice During Global Antibiotics Initiative Launch

On July 9, the Cystic Fibrosis Foundation's President and CEO, Dr. Michael P. Boyle, participated in the global launch of the AMR Action Fund. Alongside leaders in global health, Dr. Boyle highlighted the critical need of antibiotics for people living with CF and stressed that research investment alone will not solve the challenges of antibiotic development.

| 3 min read